HSTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HealthStream Inc (HSTM) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance shows declining profitability, insiders are selling shares, and there are no significant positive catalysts or trading signals to support a buy decision. While the stock has potential for slight short-term gains, it does not align well with a long-term investment strategy focused on stable growth.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is in the neutral zone, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a lack of strong upward trend. The stock is trading near its resistance levels (R1: 21.194, R2: 21.614), which could limit further upside in the short term.
The MACD indicates some bullish momentum, and the stock has an 80% chance to rise 2.61% in the next week and 15.47% in the next month. Analysts have noted that HealthStream is favorably positioned against AI disintermediation concerns.
Insiders are selling shares significantly (+146.37% over the last month), and hedge funds are neutral. The company's financial performance in Q4 2025 showed a sharp decline in net income (-48.17% YoY) and EPS (-43.75% YoY). There is no recent news or significant event-driven catalyst to support a strong buy decision.
In Q4 2025, revenue increased by 7.37% YoY to $79.71 million, but net income dropped by 48.17% YoY to $2.53 million. EPS also declined by 43.75% YoY to $0.09, and gross margin fell by 4.07% YoY to 49.96%. This indicates declining profitability despite revenue growth.
Canaccord recently lowered the price target from $25 to $21 and maintained a Hold rating. Analysts expressed concerns about AI disintermediation but acknowledged that HealthStream is better positioned than other SaaS companies in this regard.
